2851862-91-2
2851862-91-2
Chemical Structure
Gocatamig
Synonym(s): MK-6070; HPN328
- CAS No.: 2851862-91-2
- Formula:N/A
- Molecular Weight:(53.058 kDa)
SMILES: [Gocatamig]
Biological Activity: Gocatamig is a (scFv-heavy-lamdba)-VH-VH'-type chimeric humanized antibody targeting CD3E/ALB/DLL3. Gocatamig binds DLL3 on tumor cells, recruits T cells, induces T cell-mediated cytotoxicity, and redirects T cells to mediate antitumor activity. Gocatamig can be used in research related to small cell lung cancer, prostate cancer, and neuroendocrine tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gocatamig | ≥99.0% | Gocatamig is a (scFv-heavy-lamdba)-VH-VH'-type chimeric humanized antibody targeting CD3E/ALB/DLL3. Gocatamig binds DLL3 on tumor cells, recruits T cells, induces T cell-mediated cytotoxicity, and redirects T cells to mediate antitumor activity. Gocatamig can be used in research related to small cell lung cancer, prostate cancer, and neuroendocrine tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Eisen C, et al. 2791P Advancing SCLC biomarker discovery: AI-driven MHC-I quantification and impact of MHC-I on the tumor microenvironment. Annals of Oncology. 2025 Sep 1;36:S1484.
- [2]. Beltran H, et al. Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
